0.940
0.48 (103.48%)
| Previous Close | 0.462 |
| Open | 0.604 |
| Volume | 196,416,463 |
| Avg. Volume (3M) | 760,832 |
| Market Cap | 48,287,784 |
| Price / Sales | 0.210 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2026 |
| Profit Margin | -41.02% |
| Operating Margin (TTM) | -18.89% |
| Diluted EPS (TTM) | -1.04 |
| Quarterly Revenue Growth (YOY) | 22.50% |
| Total Debt/Equity (MRQ) | 1,407.14% |
| Current Ratio (MRQ) | 2.00 |
| Operating Cash Flow (TTM) | -15.65 M |
| Levered Free Cash Flow (TTM) | 10.01 M |
| Return on Assets (TTM) | -9.57% |
| Return on Equity (TTM) | -1,552.23% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | MDxHealth SA | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.67 |
|
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 13.22% |
| % Held by Institutions | 43.04% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mvm Partners, Llc | 31 Mar 2026 | 4,700,457 |
| Panoramic Capital, Llc | 31 Mar 2026 | 238,668 |
| Landscape Capital Management, L.L.C. | 31 Mar 2026 | 163,655 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |